Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia

13 juin 2017 mis à jour par: Hoffmann-La Roche

Efficacy of C.E.R.A. for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients on Dialysis , Treated According to Routine Clinical Practice

This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.

Aperçu de l'étude

Statut

Complété

Les conditions

Anémie

Type d'étude

Observationnel

Inscription (Réel)

127

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Inde
- - Ahmedabad, Inde, 380005
    - Ahmedabad Dialysis Centre
  - Guwahati, Inde, 781007
    - Excel Center
  - Kolkata, Inde, 600054
    - ESIS Hospital; Department of Nephrology
  - Mumbai, Inde, 400083
    - Vertex Hospital
  - New Delhi, Inde, 110076
    - Apollo Indraprastha Hospitals; Nephrology
  - Pune, Inde, 411033
    - Aditya Birla Memorial Hospital
- Delhi
  - New Delhi, Delhi, Inde, 110060
    - Sir Gangaram Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Patients with chronic kidney disease on dialysis receiving treatment with Mircera for chronic renal anemia

La description

Inclusion Criteria:

Adult patients, 18 to 65 years of age, inclusive
Patients with chronic kidney disease on dialysis
ESA naïve with Hb < 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 10-12 g/dL
Adequate irons status as judged by the treating physician

Exclusion Criteria:

Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
Clinically significant concomitant disease or disorder as defined by protocol
Clinical suspicion of pure red cell aplasia (PRCA)
Planned elective surgery during the study period , except for cataract surgery or vascular access surgery
Transfusion of red blood cells in the previous 2 months
Pregnant women
Contraindications for Mircera according to local prescribing information or as judged by the investigator

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Nombre de groupes / cohortes

Cohortes et interventions

Groupe / Cohorte
Cohorte

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats	Description de la mesure	Délai
Mean Age of Participants Treated With C.E.R.A Délai: Baseline (Week 0)	Age was calculated on screening/Baseline visit day by using formula: Age = (Screening visit date - Date of birth)/365.25	Baseline (Week 0)
Mean Weight of Participants Treated With C.E.R.A Délai: Baseline (Week 0)	Weight of the participants was measured at the Baseline and summarized with descriptive statistics.	Baseline (Week 0)
Number of Participants With Co-morbidity Treated With C.E.R.A Délai: Up to Week 24	Co-morbidity is the presence of one or more additional disorders (or diseases) co-occurring with a primary disease or disorder; or the effect of such additional disorders or diseases. Co-morbid participants with renal and urinary disorders, vascular disorders, metabolism and nutrition disorders were reported.	Up to Week 24
Mean Time Required to Achieve Target Hemoglobin Range Délai: Up to Week 24	The target range of hemoglobin (Hb) was 10-12 gram/deciliter (g/dL). Time to achieve target range = (Date of Hb evaluation when participant achieved target Hb range at first time - visit date of first dosing) + 1	Up to Week 24
Percentage of Participants Achieved Target Range of Hemoglobin Délai: Up to Week 24	The target range of Hb was 10-12 gram/deciliter (g/dL). Time to achieve target range = (Date of Hb evaluation when participant achieved target Hb range at first time - visit date of first dosing) + 1. The percentage of participants with Hb < 10 g/dL at enrollment, achieving the target range of hemoglobin 10-12 g/dL was reported.	Up to Week 24
Percentage of Participants Who Had Received Treatment With Other Erythropoiesis-Stimulating Agents Maintaining Hb Level Within 1 Gram/Deciliter of Baseline Value During Study Period in Participants. Délai: Up to Week 24	Percentage of participants maintaining Hb level within 1 g/dL of baseline value during study period who had received treatment with other Erythropoiesis-Stimulating Agents (ESAs) were reported.	Up to Week 24

Mesures de résultats secondaires

Mesure des résultats	Description de la mesure	Délai
Number of Participants Achieving Hb Target Range (10-12 Hb g/dL) at Least Once During the Study Délai: Up to Week 24	For correction of anemia, number of participants achieving Hb target range (10-12 g/dL) at least once during the study were reported.	Up to Week 24
Mean Time Spent by Participants in the Hb Target Range Délai: Up to Week 24	Maintenance of target Hb was evaluated by assessing the mean time spent by participants in target Hb range. The target Hb range in the study was 10-12 g/dL.	Up to Week 24
Evaluation of Route of Administration for C.E.R.A Délai: Up to Week 24	C.E.R.A. was administered by Intravenous (IV) and Subcutaneous (SC) route of administration. The frequency (number of injections) for both of these routes of administration used in the study was reported.	Up to Week 24
Evaluation of Dose Per Injection of C.E.R.A Délai: Up to Week 24	The dosing and titration of C.E.R.A treatment were at the discretion of the investigator in accordance with local clinical practice or approved prescribing information. Mean dose per injection of C.E.R.A received by participants was reported.	Up to Week 24
Number of Participants Received Concomitant Medications Délai: Up to Week 24	Medications that were used during the study treatment period (from the first dose date of study medication to the end of the study) were included as concomitant medications. The prescribed concomitant medications (in greater than or equal to 10% of participants) in the study were prazosin, torasemide, vitamin and nutritional supplements, omeprazole, amlodipine, calcium supplements, calcitriol, and clonidine. Participants treated with the each of these concomitant medications were reported.	Up to Week 24

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Hoffmann-La Roche

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 avril 2011

Achèvement primaire (Réel)

30 septembre 2013

Achèvement de l'étude (Réel)

30 septembre 2013

Dates d'inscription aux études

Première soumission

30 août 2012

Première soumission répondant aux critères de contrôle qualité